Acquired Immunodeficiency Syndrome (AIDS - HIV)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
HIV infects immune cells, especially CD4+ T cells. AIDS is the most advanced stage of HIV infection, when severe immune damage or certain defining illnesses occur. It increases vulnerability to serious infections and cancers. Effective antiretroviral therapy (ART) can prevent progression and help restore immune function, including after an AIDS diagnosis.
Clinical Definition
AIDS is advanced HIV infection, characterized in adults by a CD4 count below 200 cells/μL or an AIDS-defining illness, such as Pneumocystis pneumonia or Kaposi sarcoma, regardless of CD4 count. HIV is a retrovirus: reverse transcriptase converts viral RNA to DNA, and integrase inserts that DNA into the host genome. Persistent infection and CD4 depletion impair cell-mediated immunity.
Inciting Event
Exposure to infected bodily fluids such as blood, semen, vaginal secretions, or breast milk.
Initial infection typically occurs via mucosal surfaces during sexual contact.
Needle-stick injury or sharing of contaminated injection equipment.
Vertical transmission from an HIV-positive mother to her child.
Rarely, transmission through blood transfusion with infected blood products.
Latency Period
Acute HIV symptoms may appear 2-4 weeks after acquisition, but some people have no symptoms.
The chronic phase can remain asymptomatic for years; without effective ART, immune damage continues.
Without ART, progression to AIDS often takes about a decade, but can be faster or slower; effective treatment can prevent progression.
Opportunistic-infection risk rises as CD4 falls, especially below 200 cells/μL; thresholds differ by infection and some occur at higher counts.
Latency duration varies based on viral strain, host genetics, and treatment.
Diagnostic Delay
Early symptoms are often nonspecific and mistaken for common viral illnesses.
Lack of routine HIV screening in asymptomatic individuals delays diagnosis.
Stigma and fear may prevent patients from seeking timely testing.
Misattribution of symptoms to other chronic infections or malignancies.
Limited access to healthcare and diagnostic facilities in resource-poor settings.
Clinical Presentation
Signs & Symptoms
Fever, night sweats, and weight loss as constitutional symptoms of HIV infection.
Chronic diarrhea due to opportunistic gastrointestinal infections.
Oral thrush and esophagitis from Candida albicans overgrowth.
Progressive cognitive decline or focal neurologic signs indicating CNS involvement.
Recurrent bacterial infections due to immunodeficiency.
History of Present Illness
Initial presentation may include fever, lymphadenopathy, rash, and pharyngitis during acute infection.
An asymptomatic interval may precede weight loss, chronic diarrhea and night sweats in untreated or uncontrolled HIV.
Development of opportunistic infections such as Pneumocystis jirovecii pneumonia or Candida esophagitis.
Neurologic symptoms like memory loss, confusion, or focal deficits may appear in advanced disease.
Patients often report recurrent infections and persistent fatigue as immunodeficiency worsens.
Past Medical History
History of sexually transmitted infections increases suspicion for HIV.
Previous blood transfusions or organ transplants before screening implementation.
Intravenous drug use with shared needles is a significant risk factor.
Prior episodes of opportunistic infections or unusual malignancies suggest immunodeficiency.
Lack of prior HIV testing or incomplete antiretroviral therapy adherence.
Family History
No direct hereditary transmission, but vertical transmission from mother to child is critical.
Family relationship or ordinary household contact does not transmit HIV; assess specific sexual, blood or perinatal exposures.
Homozygous CCR5-Δ32 reduces susceptibility to CCR5-tropic HIV-1, but is not universal protection; infection using other coreceptors can occur.
AIDS is an acquired consequence of HIV, not an inherited immunodeficiency syndrome.
Offer testing according to routine screening and actual exposure history; living with a family member who has HIV is not itself an exposure.
Physical Exam Findings
Generalized lymphadenopathy often present in early HIV infection.
Oral candidiasis with white plaques that can be scraped off the mucosa.
Kaposi sarcoma lesions appearing as violaceous plaques or nodules on the skin or mucosa.
Cachexia and wasting syndrome in advanced AIDS due to chronic infection and malnutrition.
Cognitive impairment can accompany HIV-associated neurocognitive disorders. New focal weakness or other focal deficits require prompt evaluation, including for CNS opportunistic infection or lymphoma.
Diagnostic Workup
Diagnostic Criteria
For adults, begin with a laboratory HIV-1/2 antigen/antibody assay. A reactive screen is followed by an HIV-1/2 antibody differentiation assay; use HIV RNA testing when differentiation is negative or indeterminate, or acute infection is suspected despite negative screening. In confirmed HIV, adult AIDS (stage 3) is defined by CD4 <200 cells/μL or an AIDS-defining illness; CD4 percentage <14% applies if the absolute count is unavailable. An undetectable viral load during treatment does not exclude established HIV.
Pathophysiology
Key Mechanisms
HIV infects and depletes CD4+ T cells, leading to progressive immunodeficiency.
Reverse transcriptase synthesizes viral DNA from RNA; integrase then inserts the viral DNA into the host genome.
Chronic immune activation causes immune exhaustion and lymphoid tissue destruction.
Loss of cell-mediated immunity predisposes to opportunistic infections and malignancies.
Viral mutation leads to immune evasion and resistance to antiretroviral therapy.
| Involvement | Details |
|---|---|
| Organs | Lymph nodes are critical sites of HIV replication and immune cell interaction. |
Brain can be affected by HIV-associated neurocognitive disorders due to viral invasion and inflammation. | |
Lungs are commonly involved in opportunistic infections in AIDS patients. | |
| Tissues | Lymphoid tissue is a major site of HIV replication and CD4+ T cell depletion. |
Gut-associated lymphoid tissue (GALT) is an early and significant site of CD4+ T cell loss in HIV infection. | |
| Cells | CD4+ T cells are the primary target of HIV infection and their depletion leads to immunodeficiency. |
Macrophages serve as reservoirs for HIV and contribute to viral persistence and dissemination. | |
Dendritic cells facilitate HIV transmission to T cells and initiate immune responses. | |
| Chemical Mediators | Cytokines such as IL-2 and TNF-alpha are dysregulated in HIV infection, contributing to immune activation and pathogenesis. |
Reverse transcriptase is the viral enzyme targeted by multiple antiretroviral drugs to inhibit HIV replication. | |
Integrase is a viral enzyme essential for integration of HIV DNA into the host genome and a key drug target. |
Treatments
Pharmacological Treatments
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
- Mechanism:
Nucleoside/nucleotide analogs inhibit HIV reverse transcriptase, commonly through termination of viral DNA synthesis.
- Side effects:
Tenofovir-related renal toxicity, especially with TDF
Reduced bone mineral density, more prominent with TDF than TAF
Abacavir hypersensitivity, especially with HLA-B*5701
- Clinical role:
Components of combination ART, commonly with an INSTI. Selection depends on renal function, hepatitis B status and other factors; check HLA-B*5701 before abacavir.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Mechanism:
Bind directly to HIV reverse transcriptase causing allosteric inhibition of viral DNA synthesis.
- Side effects:
Rash
Hepatotoxicity
Neuropsychiatric symptoms, particularly with efavirenz
- Clinical role:
Selected combination regimens when appropriate; NNRTIs are not the preferred initial anchor for most adults. Consider resistance and interactions.
Protease Inhibitors (PIs)
- Mechanism:
Inhibit HIV protease, preventing cleavage of viral polyproteins and production of mature infectious virions.
- Side effects:
Hyperlipidemia
Insulin resistance
Lipodystrophy
- Clinical role:
Boosted darunavir is used in selected initial or treatment-experienced regimens, including some resistance scenarios. Review drug interactions.
Integrase Strand Transfer Inhibitors (INSTIs)
- Mechanism:
Block HIV integrase enzyme, preventing integration of viral DNA into host genome.
- Side effects:
Insomnia
Headache
Weight gain with some INSTI regimens; creatine kinase elevation is also reported with agents such as raltegravir
- Clinical role:
Bictegravir- or dolutegravir-based combination ART is preferred for most adults starting treatment; select the complete regimen for the individual. Do not use INSTI monotherapy.
CCR5 Antagonists
- Mechanism:
Block CCR5 co-receptor on host cells, preventing HIV entry.
- Side effects:
Hepatotoxicity
Respiratory infections
- Clinical role:
Maraviroc is a selected combination-ART option only when testing confirms CCR5-tropic HIV-1; it is not a universal second-line drug.
Fusion Inhibitors
- Mechanism:
Prevent fusion of HIV envelope with host cell membrane by binding gp41.
- Side effects:
Injection site reactions
Bacterial pneumonia signal reported in trials; causality remains uncertain, but monitor for symptoms
- Clinical role:
Enfuvirtide is used with other active agents in selected treatment-experienced patients with ongoing HIV-1 replication despite ART.
Non-pharmacological Treatments
Risk-reduction counseling and condoms help prevent transmission and other STIs; these are adjuncts to HIV care, not substitutes for ART.
Regular monitoring of CD4 count and viral load to guide therapy and detect treatment failure.
Nutrition and supportive care complement ART and pathogen-specific treatment of opportunistic infections.
Counseling and psychosocial support to enhance adherence to antiretroviral therapy.
Prevention
Pharmacological Prevention
PrEP is for people without HIV, after appropriate HIV testing. Options include oral TDF/emtricitabine; select the regimen for exposure type and clinical factors. TAF/emtricitabine is not indicated for receptive vaginal exposure. PrEP alone is not treatment for established HIV.
After a qualifying exposure, start PEP as soon as possible and no later than 72 hours. A 28-day, three-drug course and follow-up HIV testing are required; do not delay initiation while awaiting laboratory results.
ART is recommended for everyone with HIV, regardless of CD4 count, and usually starts promptly. Certain CNS infections, including cryptococcal or TB meningitis, require specialist-guided timing because early ART can worsen IRIS.
TMP-SMX is preferred for primary PCP prophylaxis. Start if CD4 <200 cells/μL when not on ART or starting ART. During established ART, use prophylaxis at CD4 <100 regardless of RNA, or 100-200 with sustained detectable HIV RNA; reassess after immune recovery.
Vaccination against preventable infections like pneumococcus and influenza.
Non-pharmacological Prevention
Consistent condom use to reduce sexual transmission of HIV.
Needle exchange programs to prevent transmission among intravenous drug users.
Routine opt-out HIV screening: CDC recommends at least one test at ages 13-64, at least annual testing with ongoing risk, and testing during every pregnancy.
Safe blood transfusion practices to avoid HIV transmission.
Counseling and education on risk reduction and adherence to therapy.
Outcome & Complications
Complications
Opportunistic infections such as Pneumocystis jirovecii pneumonia and toxoplasmosis.
AIDS-defining malignancies including Kaposi sarcoma and non-Hodgkin lymphoma.
HIV-associated neurocognitive disorders ranging from mild impairment to dementia.
Immune reconstitution inflammatory syndrome (IRIS) after initiation of antiretroviral therapy.
Wasting syndrome with severe weight loss and muscle atrophy.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Acquired Immunodeficiency Syndrome (AIDS - HIV) versus Primary Immunodeficiency Disorders
Acquired Immunodeficiency Syndrome (AIDS - HIV) | Primary Immunodeficiency Disorders |
|---|---|
Advanced HIV can occur at any age after a variable period of untreated or uncontrolled infection | May present in childhood or adulthood; CVID is often diagnosed in adults |
Characterized by progressive depletion of CD4+ T cells | Often involves congenital defects in B cells, T cells, or phagocytes with variable lymphocyte counts |
Established by the HIV testing algorithm; viral RNA may be undetectable on effective ART | Immunologic evaluation guides diagnosis; genetic testing may identify a cause but is not always definitive |
Acquired Immunodeficiency Syndrome (AIDS - HIV) versus Acute Viral Infections (e.g., Infectious Mononucleosis)
Acquired Immunodeficiency Syndrome (AIDS - HIV) | Acute Viral Infections (e.g., Infectious Mononucleosis) |
|---|---|
Persistent HIV infection; untreated disease may progress, while effective ART can prevent progression | Uncomplicated infectious mononucleosis usually improves over weeks, although fatigue may persist |
Advanced untreated HIV often has substantial CD4 depletion | EBV mononucleosis often produces atypical lymphocytosis; patterns differ among other viral infections |
Use the HIV testing algorithm; request RNA when acute infection is suspected despite negative screening | Primary EBV infection is supported by VCA IgM with absent EBNA; a heterophile test alone does not confirm EBV |
Acquired Immunodeficiency Syndrome (AIDS - HIV) versus Chronic Corticosteroid Use
Acquired Immunodeficiency Syndrome (AIDS - HIV) | Chronic Corticosteroid Use |
|---|---|
HIV and immunosuppressive medication exposure can coexist; medication history does not exclude HIV | Assess corticosteroid dose, duration and indication as contributors to immunosuppression |
CD4 depletion is characteristic, alongside broader immune dysfunction | Corticosteroids suppress immune responses; clinical effects depend on dose, duration and other risk factors |
Requires antiretroviral therapy for immune restoration | Reduce chronic corticosteroids only when clinically appropriate, using a supervised taper that accounts for adrenal suppression |
Acquired Immunodeficiency Syndrome (AIDS - HIV) versus Tuberculosis (TB) Infection
Acquired Immunodeficiency Syndrome (AIDS - HIV) | Tuberculosis (TB) Infection |
|---|---|
Caused by HIV, a retrovirus | Caused by Mycobacterium tuberculosis |
HIV and TB may coexist; advanced immunosuppression can produce atypical or noncavitary TB imaging | Pulmonary TB may be upper-lobe cavitary, miliary or atypical; chest radiographs can be normal in advanced HIV |
Confirm HIV using its testing algorithm; HIV results do not rule out TB | Evaluate appropriate specimens with molecular testing and mycobacterial culture; AFB smear alone does not establish M. tuberculosis |
Acquired Immunodeficiency Syndrome (AIDS - HIV) versus Leukemia or Lymphoma
Acquired Immunodeficiency Syndrome (AIDS - HIV) | Leukemia or Lymphoma |
|---|---|
CD4 depletion does not exclude a coexisting hematologic malignancy | Blood or marrow abnormalities depend on subtype; lymphoma may lack circulating blasts |
Uncontrolled HIV can cause chronic immune dysfunction and opportunistic illness; lymphoma may coexist | Course varies from indolent to aggressive; AIDS-related lymphomas are commonly aggressive |
Confirmed HIV can coexist with malignancy, including AIDS-defining lymphoma | Lymphoma generally requires affected tissue biopsy; suspected leukemia requires blood/marrow characterization as appropriate |